Yazar "Karasu, Gulsun Tezcan" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    Hematopoietic Stem Cell Transplantation Using Preimplantation Genetic Diagnosis and Human Leukocyte Antigen Typing for Human Leukocyte Antigen-Matched Sibling Donor: A Turkish Multicenter Study
    (Elsevier Science Inc, 2017) Kurekci, Emin; Kupesiz, Alphan; Anak, Sema; Ozturk, Gulyuz; Gursel, Orhan; Aksoylar, Serap; Ileri, Talia; Kuskonmaz, Baris; Eker, Ibrahim; Cetin, Mualla; Karasu, Gulsun Tezcan; Kaya, Zuhre; Fisgin, Tunc; Ertem, Mehmet; Kansoy, Savas; Yesilipek, Mehmet Akif
    Preimplantation genetic diagnosis involves the diagnosis of a genetic disorder in embryos obtained through in vitro fertilization, selection of healthy embryos, and transfer of the embryos to the mother's uterus. Preimplantation genetic diagnosis has been used not only to avoid the risk of having an affected child, but it also offers, using HLA matching, preselection of potential HLA-genoidentical healthy donor progeny for an affected sibling who requires bone marrow transplantation. Here, we share the hematopoietic stem cell transplantation results of 52 patients with different benign and malign hematological or metabolic diseases or immunodeficiencies whose donors were siblings born with this technique in Turkey since 2008. The median age of the patients' at the time of the transplantation was 8 years (range, 3 to 16 years) and the median age of the donors was 2 years (range,.5 to 6 years). The most common indication for HSCT was thalassemia major (42 of all patients, 80%). The stem cell source in all of the transplantations was bone marrow. In 37 of the transplantations, umbiliCal cord blood of the same donor was also used. In 50 of the 52 patients, full engraftment was achieved with a mean of 4.6 x 10(6) CD 34(+) cells per kg of recipient weight. Ninety-six percent of the patients have been cured through hematopoietic stem cell transplantation without any complication. Primary engraftment failure was seen in only 2 patients with thalassemia major. All of the donors and the patients are alive with good health status. Preimplantation genetic diagnosis with HLA matching offers a life-saving chance for patients who need transplantation but lack an HLA genoidentical donor. (C) 2017 American Society for Blood and Marrow Transplantation.
  • Küçük Resim Yok
    Öğe
    Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry
    (Wiley, 2019) Karapinar, Deniz Yilmaz; Patiroglu, Turkan; Metin, Ayse; Caliskan, Umran; Celkan, Tiraje; Yilmaz, Baris; Karakas, Zeynep; Karapinar, Tuba H.; Akinci, Burcu; Özkınay, Ferda; Onay, Huseyin; Yesilipek, Mehmet Akif; Akar, Himmet Haluk; Tuysuz, Gulen; Tokgoz, Huseyin; Ozdemir, Gul Nihal; Kiykim, Ayca Aslan; Karaman, Serap; Kilinc, Yurdanur; Oymak, Yesim; Kupesiz, Alphan; Olcay, Lale; Yildirim, Zuhal Keskin; Aydogan, Gonul; Gokce, Muge; Ileri, Talia; Aral, Yusuf Ziya; Bay, Ali; Atabay, Berna; Kaya, Zuhre; Soker, Murat; Karadas, Nihal Ozdemir; Ozbek, Ugur; Selcuk, Bilge Ozsait; Ozdemir, Hamiyet Hekimci; Uygun, Vedat; Karasu, Gulsun Tezcan; Yilmaz, Sebnem
    Background Severe congenital neutropenia is a rare disease, and autosomal dominantly inherited ELANE mutation is the most frequently observed genetic defect in the registries from North America and Western Europe. However, in eastern countries where consanguineous marriages are common, autosomal recessive forms might be more frequent. Method Two hundred and sixteen patients with severe congenital neutropenia from 28 different pediatric centers in Turkey were registered. Results The most frequently observed mutation was HAX1 mutation (n = 78, 36.1%). A heterozygous ELANE mutation was detected in 29 patients (13.4%) in our cohort. Biallelic mutations of G6PC3 (n = 9, 4.3%), CSF3R (n = 6, 2.9%), and JAGN1 (n = 2, 1%) were also observed. Granulocyte colony-stimulating factor treatment was given to 174 patients (80.6%). Two patients died with infectious complications, and five patients developed myelodysplastic syndrome/acute myeloblastic leukemia. The mean (+/- mean standard error) follow-up period was 129.7 +/- 76.3 months, and overall survival was 96.8% (CI, 94.4-99.1%) at the age of 15 years. In Turkey, severe congenital neutropenia mostly resulted from the p W44X mutation in the HAX1 gene. Conclusion In Turkey, mutation analysis should be started with HAX1, and if this is negative, ELANE and G6PC3 should be checked. Because of the very high percentage of consanguineous marriage, rare mutations should be tested in patients with a negative mutation screen.
  • Küçük Resim Yok
    Öğe
    Relapse after allogeneic hematopoietic stem cell transplantation for acute leukemia in children: a survey by the Turkish Pediatric Bone Marrow Study Group of 255 cases
    (Nature Publishing Group, 2018) Hazar, Volkan; Karasu, Gulsun Tezcan; Ozturk, Gulyuz; Kupesiz, Alphan; Kansoy, Savas; Ozbek, Namik; Kilic, Suar Caki
    [No Abstract Available]
  • Küçük Resim Yok
    Öğe
    Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group
    (Oxford Univ Press, 2019) Hazar, Volkan; Karasu, Gulsun Tezcan; Uygun, Vedat; Ozturk, Gulyuz; Kilic, Suar Caki; Kupesiz, Alphan; Daloglu, Hayriye; Aksoylar, Serap; Atay, Didem; Ince, Elif Unal; Karakukcu, Musa; Ozbek, Namik; Tayfun, Funda; Kansoy, Savas Comma; Ozyurek, Emel; Akcay, Arzu; Gursel, Orhan; Haskologlu, Sule; Kaya, Zuhre; Yilmaz, Sebnem; Tanyeli, Atila; Yesilipek, Akif
    Invasive fungal infections (IFIs) are a major cause of infection-related morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Data from pediatric settings are scarce. To determine the incidence, risk factors and outcomes of IFIs in a 180-day period post-transplantation, 408 pediatric patients who underwent allogeneic HSCT were retrospectively analyzed. The study included only proven and probable IFIs. The cumulative incidences of IFI were 2.7%, 5.0%, and 6.5% at 30, 100, and 180 days post-transplantation, respectively. According to the multivariate analysis, the factors associated with increased IFI risk in the 180-day period post-HSCT were previous HSCT history (hazard ratio [HR], 4.57; 95% confidence interval [CI] 1.42-14.71; P =.011), use of anti-thymocyte globulin (ATG) (HR, 2.94; 95% CI 1.27-6.80; P =.012), grade III-IV acute graft-versus-host-disease (GVHD) (HR, 2.91; 95% CI 1.24-6.80; P =.014) and late or no lymphocyte engraftment (HR, 2.71; 95% CI 1.30-5.62; P =.007). CMV reactivation was marginally associated with an increased risk of IFI development (HR, 1.91; 95% CI 0.97-3.74; P =.063). IFI-related mortality was 1.5%, and case fatality rate was 27.0%. The close monitoring of IFIs in pediatric patients with severe acute GVHD who receive ATG during conditioning is critical to reduce morbidity and mortality after allogeneic HSCT, particularly among those with prior HSCT and no or late lymphocyte engraftment.
  • Küçük Resim Yok
    Öğe
    Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group
    (Taylor & Francis Ltd, 2020) Hazar, Volkan; Karasu, Gulsun Tezcan; Uygun, Vedat; Ozbek, Namik; Karakukcu, Musa; Ozturk, Gulyuz; Ok Bozkaya, Ikbal
    We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. the nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. the Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.
  • Küçük Resim Yok
    Öğe
    Turkish National Severe Congenital Neutropenia Registry
    (Amer Soc Hematology, 2016) Karapinar, Deniz Yilmaz; Karakas, Zeynep; Patiroglu, Turkan; Metin, Ayse; Caliskan, Umran; Celkan, Tiraje; Yilmaz, Baris; Karapinar, Tuba H.; Karaman, Serap; Akinci, Burcu; Akar, Himmet Haluk; Tokgoz, Huseyin; Ozdemir, Gul Nihal; Kiykim, Ayca Aslan; Kilinc, Yurdanur; Oymak, Yesim; Olcay, Lale; Bor, Ozcan; Yildirim, Zuhal Keskin; Gokce, Muge; Erduran, Erol; Ileri, Dilber Talia; Aral, Yusuf Ziya; Bay, Ali; Atabay, Berna; Kaya, Zuhre; Onay, Huseyin; Özkınay, Ferda; Selcuk, Bilge Ozsait; Ozbek, Ugur; Karasu, Gulsun Tezcan; Bengoa, Sebnem Yilmaz; Yesilipek, Akif